COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech
30/05/2025
EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech Avec l’acquisition de cette plateforme d'ophtalmologie de premier plan auprès de MidEuropa, le Groupe vise à [...]
EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy
30/05/2025
EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy Acquisition of leading ophthalmology platform from MidEuropa will advance the Group’s development of the most comprehensive and [...]
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
30/05/2025
Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 months Survival has currently reached plateau, with 34% (7/20) of patients still [...]
Le Québec a les cartes en main pour réduire les impacts des écrans sur la santé des jeunes
30/05/2025
MONTRÉAL, 30 mai 2025 (GLOBE NEWSWIRE) -- Après plusieurs mois de travaux et de consultations, la Commission spéciale sur les impacts des écrans et des réseaux sociaux sur la santé et le développement des jeunes (CSESJ [...]
Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO
30/05/2025
L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des [...]
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
30/05/2025
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of [...]
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
30/05/2025
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment Phase III studies for fenebrutinib in relapsing and primary [...]
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
30/05/2025
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit [...]
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
29/05/2025
WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Cytokinetics to Participate in the Jefferies Global Healthcare Conference
29/05/2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at [...]
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
29/05/2025
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June: Jefferies 2025 Global [...]
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/05/2025
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
29/05/2025
– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice- [...]
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
29/05/2025
SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
29/05/2025
FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
29/05/2025
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
Amneal to Participate at Upcoming Investor Conferences in June
29/05/2025
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company [...]
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
29/05/2025
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimization The study is currently enrolling in dose escalation [...]
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
29/05/2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery [...]

Pages